Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store.
Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777.
A link to the prescribing information can be found in the header.
Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex) is indicated for symptomatic treatment of focal spasticity of:
- Dynamic equinus foot deformity in ambulant paediatric cerebral palsy patients, two years of age or older
- Upper limbs in paediatric cerebral palsy patients, two years of age or older.
Please click here to see the full therapeutic indications.
CLIMB Online
Paediatric Spasticity
Dysport® Dilution Guide
2 pages
A downloadable reference guide to reconstituting and diluting Dysport®
DYS-UK-007576
BoNT Immunogenicity: The difference between neutralising and non-neutralising antibodies
3 minutes
Understand the difference between neutralising and non-neutralising antibodies and how this difference should be considered during clinical decision-making.
DYS-UK-007538
Demystifying the Clinical Relevance of BoNT Immunogenicity
5 minutes
Learn about the difference between neutralising and non-neutralising antibodies, and factors to consider when investigating non-response to BoNT treatment
Presented by: Dr Tim Harrower
DYS-UK-007574
Dysport® Mechanism of Action
3 minutes
DYS-UK-007580
© IPSEN Ltd, 5th Floor The Point, 37 North Wharf Road, London, W2 1AF, United Kingdom. All rights reserved. February 2024 DYS-UK-008401
